The Effect of Combination Therapy with Rituximab and Intravenous Immunoglobulin on the Progression of Chronic Antibody Mediated Rejection in Renal Transplant Recipients

<table>Changes in ΔeGFR values in 7 patients with long-term followup over 12 months. With time, ΔeGFR gradually decreased at every 6-month interval and the ΔeGFR at 12 months from RIT and that at the last followup showed similar values compared to that observed 6 months before RIT.</table>

Journal of Immunology Research

fig3

Figure 3

Figure 3: The Effect of Combination Therapy with Rituximab and Intravenous Immunoglobulin on the Progression of Chronic Antibody Mediated Rejection in Renal Transplant Recipients 

Figure 3 | The Effect of Combination Therapy with Rituximab and Intravenous Immunoglobulin on the Progression of Chronic Antibody Mediated Rejection in Renal Transplant Recipients 